

Hollis-Eden Pharmaceuticals, Inc.

4435 Eastgate Mall, Suite 400

San Diego, CA 92121

Telephone: 858 587 9333

Fax: 858 558 6470



HOLLISEDEN
PHARMACEUTICALS
Serving Humanity

1623
RECEIVED
MAR 05 2003
TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE OF MAILING BY "FIRST-CLASS MAIL"

Attorney Docket No. : 202.3

Serial No. : 09/820,483

Applicant(s) : Clarence N. Ahlem, et al.

For : Immune Modulation Method Using Steroid Compounds

Attorney : Daryl D. Muenchau, Registration No. 36,616

I hereby certify that the accompanying

Information Disclosure Statement Transmittal; Information Disclosure Statement
(Form 1449-in duplicate) with cited references (2); and Return Prepaid Postcard

are being deposited with the United States Postal Service "First-Class Mail" service on the date indicated below and are addressed to the United States Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202, ATTN: Box DD.

2/28/03
Date of Deposit

Vickie L. Cowan
Vickie L. Cowan



PATENT
Docket No. 202.3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Clarence N. Ahlem, et al.)	Group Art Unit 1623
)	
App. No.	:	09/820,483)	
)	
Filed	:	March 29, 2001)	
)	
For	:	IMMUNE MODULATING)	
		METHOD USING STEROID)	
		COMPOUNDS)	
)	
Examiner	:	E. Peselev)	

RECEIVED
MAR 05 2003
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:


Enclosed is form PTO-1449 (in duplicate) listing references that are also enclosed. No fee is required in accordance with 37 C.F.R. § 1.97(b)(1).

Respectfully submitted,

HOLLIS-EDEN PHARMACEUTICALS, INC.

Dated: 2-28-03

By: Daryl D Muenchau
Daryl D. Muenchau, Reg. No. 36,616
Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, California, 92121
Telephone: (858) 587-9333
Customer No. 26,551



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
202.3APPLICATION NO.
09/820,483SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT - February 24, 2003

(USE SEVERAL SHEETS IF NECESSARY)


APPLICANT
Clarence Ahlem, et al.FILING DATE
March 29, 2001GROUP
E. Peselev

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 98/03207	1/29/98	PCT				
		WO 98/05338	2/12/98	PCT				

RECEIVED
MAR 05 2003
TECH CENTER 1600/2900

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	



Hollis-Eden Pharmaceuticals, Inc.
435 Eastgate Mall, Suite 400
San Diego, CA 92121
Telephone: 858 587 9333
Fax: 858 558 6470

GB/1623
#106

HOLLISEDEN
PHARMACEUTICALS
Serving Humanity

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
MAR 05 2003
TECH CENTER 1600/2900

CERTIFICATE OF MAILING BY "FIRST-CLASS MAIL"

Attorney Docket No. : 202.3
Serial No. : 09/820,483
Applicant(s) : Clarence N. Ahlem, et al.
For : Immune Modulation Method Using Steroid Compounds
Attorney : Daryl D. Muenchau, Registration No. 36,616

I hereby certify that the accompanying

Information Disclosure Statement Transmittal; Information Disclosure Statement
(Form 1449-in duplicate) with cited references (2); and Return Prepaid Postcard

are being deposited with the United States Postal Service "First-Class Mail" service on the date indicated below and are addressed to the United States Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202, ATTN: Box DD.

2/28/03
Date of Deposit

Vickie L. Cowan
Vickie L. Cowan



PATENT
Docket No. 202.3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Clarence N. Ahlem, et al.)	Group Art Unit 1623
)	
App. No.	:	09/820,483)	
)	
Filed	:	March 29, 2001)	
)	
For	:	IMMUNE MODULATING)	
		METHOD USING STEROID)	
		COMPOUNDS)	
)	
Examiner	:	E. Peselev)	

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Enclosed is form PTO-1449 (in duplicate) listing references that are also enclosed. No fee is required in accordance with 37 C.F.R. § 1.97(b)(1).

Respectfully submitted,

HOLLIS-EDEN PHARMACEUTICALS, INC.


Dated: 2-28-03

By: Daryl D Muenchau
Daryl D. Muenchau, Reg. No. 36,616
Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, California, 92121
Telephone: (858) 587-9333
Customer No. 26,551

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT – February 24, 2003 (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. 202.3	APPLICATION NO. 09/820,483
	APPLICANT Clarence Ahlem, et al.	
	FILING DATE March 29, 2001	GROUP E. Peselev

RECEIVED
 MAR 05 2003
 TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 98/14194	4/9/98	PCT				
		WO 98/24449	6/11/98	PCT				



EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, CA 92121
Telephone: 858 587 9333
Fax: 858 558 6470



HOLLISEDEN
PHARMACEUTICALS
Serving Humanity

1623

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
MAR 05 2003
TECH CENTER 1600/2900

CERTIFICATE OF MAILING BY "FIRST-CLASS MAIL"

Attorney Docket No. : 202.3
Serial No. : 09/820,483
Applicant(s) : Clarence N. Ahlem, et al.
For : Immune Modulation Method Using Steroid Compounds
Attorney : Daryl D. Muenchau, Registration No. 36,616

I hereby certify that the accompanying

Information Disclosure Statement Transmittal; Information Disclosure Statement
(Form 1449-in duplicate) with cited references (8); and Return Prepaid Postcard

are being deposited with the United States Postal Service "First-Class Mail" service on the date indicated below and are addressed to the United States Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202, ATTN: Box DD.

2/28/03
Date of Deposit

Vickie L. Cowan
Vickie L. Cowan



PATENT
Docket No. 202.3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Clarence N. Ahlem, et al.)	Group Art Unit 1623
)	
App. No.	:	09/820,483)	
)	
Filed	:	March 29, 2001)	
)	
For	:	IMMUNE MODULATING)	
		METHOD USING STEROID)	
		COMPOUNDS)	
)	
Examiner	:	E. Peselev)	

RECEIVED
MAR 05 2003
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Enclosed is form PTO-1449 (in duplicate) listing references that are also enclosed. No fee is required in accordance with 37 C.F.R. § 1.97(b)(1).

Respectfully submitted,

HOLLIS-EDEN PHARMACEUTICALS, INC.

Dated: 2-28-03

By: Daryl D Muenchau
Daryl D. Muenchau, Reg. No. 36,616
Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, California, 92121
Telephone: (858) 587-9333
Customer No. 26,551

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
202.3APPLICATION NO.
09/820,483SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT - February 24, 2003

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Clarence Ahlem, et al.FILING DATE
March 29, 2001GROUP
E. Peselev

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 98/47516	10/29/98	PCT				
		WO 98/55074	12/10/98	PCT				
		WO 99/25192	5/27/99	PCT				
		WO 99/25333	5/27/99	PCT				
		WO 99/52532	10/21/99	PCT				
		WO 99/63841	12/16/99	PCT				
		WO 99/63973	12/16/99	PCT				
		WO 99/63974	12/16/99	PCT				

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.